In a poignant new BBC documentary filmed during the final three years of his life, Ozzy Osbourne and his wife Sharon are captured planning their return to England from their longtime home in Los Angeles. 'Sharon & Ozzy Osbourne: Coming Home,' set to air Thursday evening, follows the Black Sabbath legend as he prepares for what would become his final move. The documentary, originally conceived as a series called 'Home To Roost' in 2022, documents the couple's decision to relocate to the UK in 2025 after spending more than two decades in the United States.

The film reveals intimate moments between the couple at their Grade II listed Buckinghamshire property, Welders House, which Sharon describes as her 'little piece of heaven.' Ozzy, who was diagnosed with Parkinson's disease, expresses both apprehension and anticipation about the move. In one revealing clip, he tells his daughter Kelly, 'I wouldn't say I'm excited. I'm kind of scared to back,' while acknowledging his wife's enthusiasm for their English home. 'I'm so used to being over here now but I've got to go back. I've got a house there and your mum said it's beautiful,' the rocker admits.

Tragically, Ozzy's homecoming plans were cut short when he died of heart failure on July 22, just two weeks after performing a farewell concert with his Black Sabbath bandmates at Birmingham's Villa Park. The 76-year-old rock legend was buried in the private grounds of Welders House, the very property featured in the documentary. Sharon, who had told filmmakers 'Home is where both of us are. As long as he is with me I am alright,' now finds herself living alone at the estate they had planned to share together.

The documentary captures bittersweet moments of the couple enjoying their Buckinghamshire property this summer, with Sharon expressing interest in adding more deer to the grounds while Ozzy makes plans to fish in the lake. These ordinary domestic scenes take on deeper significance in light of Ozzy's subsequent passing. The film serves as a final testament to the couple's enduring partnership and their shared vision for retirement in England, a vision that would remain unfulfilled despite their careful preparations and heartfelt declarations about their future together.

Global medical technology company Convatec has announced plans to establish a new flagship research and development hub in Manchester as part of a £500 million investment in the United Kingdom. The FTSE100-listed firm, which specializes in products for chronic wounds, diabetes, urinary incontinence, and stomas, will relocate its R&D operations from Deeside to Bruntwood SciTech's CityLabs 4.0 facility, scheduled to open in 2027. This strategic move represents a significant commitment to the UK's life sciences sector at a time when several other pharmaceutical companies have been shifting investments overseas.

The new Manchester facility will become one of the largest centers in Convatec's global network, spanning 125,000 square feet across seven storeys in the £42 million CityLabs 4.0 building. Located on Hathersage Road facing the Manchester Royal Infirmary, St Mary's and Royal Manchester Children's Hospital, the state-of-the-art facility will focus on research in four key therapeutic areas: advanced wound care, ostomy care, continence care, and infusion care. The company cited Manchester's "vibrant life sciences ecosystem, which includes leading universities, hospitals, and research institutions" as the primary reason for selecting the location.

Approximately 200 staff will be employed at the new Manchester hub, with most positions transferring from Convatec's existing R&D operation in Deeside, North Wales, which has served as a major research center since 1996. The company emphasized that no redundancies are planned as a consequence of the relocation and that the Deeside manufacturing site will remain unaffected, continuing to employ around 400 workers. The new Manchester facility is approximately 50% larger than the current Deeside operation and has capacity for up to 250 employees, allowing for future expansion.

Convatec's investment comes as part of a broader $1 billion worldwide R&D commitment, with the UK portion representing nearly half of this global initiative. The company, which generated $2.3 billion in revenue last year, typically allocates approximately 5% of its annual revenue to research and development. The relocation to Manchester positions Convatec to leverage the city's concentration of medical research institutions, including neighboring organizations such as the University of Manchester NHS Foundation Trust, biotech company QIAGEN, and MAC Clinical Research, strengthening its pipeline of new products addressing unmet needs in chronic care.